•
Mar 31, 2022

Akoya Q1 2022 Earnings Report

Akoya reported record revenue and system placements, driven by the commercial launch of the PhenoCycler-Fusion System and execution across all business segments.

Key Takeaways

Akoya Biosciences reported a 38% increase in total revenue for Q1 2022, reaching $16.9 million compared to $12.2 million in the prior year period. The company also raised its full year 2022 revenue guidance to a range of $70-73 million.

Total revenue increased by 38% to $16.9 million compared to the prior year period.

Product revenue increased by 34% to $13.3 million, with reagent revenue increasing by 82%.

Services and other revenue increased by 58% to $3.6 million.

Gross profit increased by 36% to $10.1 million, with a gross profit margin of 60%.

Total Revenue
$16.9M
Previous year: $12.2M
+38.3%
EPS
-$0.44
Previous year: -$3.54
-87.6%
Gross Profit
$10.1M
Previous year: $7.41M
+36.3%
Cash and Equivalents
$93.9M
Previous year: $11.7M
+703.5%
Free Cash Flow
-$19.1M
Previous year: -$5.31M
+259.1%
Total Assets
$187M
Previous year: $74.5M
+151.2%

Akoya

Akoya

Akoya Revenue by Segment

Forward Guidance

The company is raising its full year 2022 revenue guidance range to $70-73 million.

Revenue & Expenses

Visualization of income flow from segment revenue to net income